Login to Your Account



Gilead's Elvitegravir Hits Phase III Endpoint in HIV

By Tom Wall


Thursday, March 24, 2011
Not bad, but not Quad. That appeared to be the general reaction of analysts to news from Gilead Sciences Inc. that elvitegravir, its oral integrase inhibitor for HIV-1 infection in treatment-experienced patients, met its primary objective in a Phase III trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription